EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ginkgolide B Inhibits Colorectal Cancer Growth via Regulation of the PI3K/AKT/MAPK Pathways: A Comprehensive Analysis Using Network Pharmacology, Molecular Docking, and Verification in Cellular and Animal Models

Qi Liu, Xin Sun, Aikelimu Aisikaer, Nyamsambuu Altannavch, Maonan Wang, Gang Yin, Guang Shu, Qing Xiao

Frontiers in Bioscience-Landmark · 16.10.2026 · 31 (10)

DOI: 10.31083/fbl55020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 16.10.2026. Verfasst von Qi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Third Xiangya Hospital, Central South University, 410013 Changsha, Hunan, China. Hauptthemen laut MEDLINE: Ginkgolides, Lactones, Colorectal Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ginkgolide B (GB), a bioactive constituent isolated from Ginkgo biloba, has shown antitumor activity in several malignancies. However, the molecular mechanisms underlying GB action against colorectal cancer (CRC) remain incompletely understood. Thus, this study aimed to systematically investigate the potential molecular mechanisms and therapeutic effects of GB on CRC using an integrated approach.

Methods

Potential therapeutic targets of GB against CRC were identified by integrating GB-related and CRC-associated genes. Protein–protein interaction (PPI) networks and functional enrichment analysis (FEA) identified key targets and pathways. Interactions between GB and hub proteins were assessed by docking. The antitumor effects of GB were evaluated in CRC cells using assays for cell proliferation, colony formation, and apoptosis, as well as Western blotting. These data were validated in an MC38 syngeneic subcutaneous tumor model.

Results

A total of 288 target proteins were shared between the 522 predicted GB targets and the 4199 CRC-associated targets. FEA indicated that these targets were primarily associated with the phosphatidylinositol 3-kinase (PI3K) / protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) axes. Docking predicted favorable binding of GB to several hub proteins, with AKT1 showing the strongest predicted affinity. Experimental validation demonstrated that GB inhibited CRC cell proliferation and colony formation, promoted apoptosis, decreased B-cell lymphoma 2 (BCL-2), increased BCL-2-associated X protein (BAX) and Cleaved Caspase-3, and reduced the phosphorylation of AKT and extracellular signal-regulated kinase (ERK). Notably, GB significantly suppressed tumor growth and reduced Ki-67 expression in the MC38 syngeneic subcutaneous tumor model.

Conclusions

GB exhibits antitumor activity against CRC by inhibiting proliferation, promoting apoptosis, and inhibiting the PI3K/AKT and MAPK pathways. The study provides a mechanistic basis for the anticancer effects of GB and supports further investigation of its potential as a therapeutic candidate for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinkgolidesLactonesColorectal NeoplasmsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMAP Kinase Signaling SystemAnimalsHumansCell ProliferationMiceMolecular Docking SimulationApoptosisNetwork PharmacologyCell Line, TumorSignal TransductionProtein Interaction Maps

Stichwörter der Autor:innen

MAP kinase signaling systemapoptosiscolorectal neoplasmsginkgolide Bphosphatidylinositol 3-kinasesproto-oncogene proteins c-akt

Substanzen

Ginkgolidesginkgolide BLactonesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Pathology, The Third Xiangya Hospital, Central South University, 410013 Changsha, Hunan, China.
  • Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, 410013 Changsha, Hunan, China.
  • Department of Pathology, School of Pharmacy, Xinjiang Medical University, 830011 Urumqi, Xinjiang, China.
  • School of Basic Medical Sciences, Central South University, 410013 Changsha, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410013 Changsha, Hunan, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Liu, Q., Sun, X., Aisikaer, A., Altannavch, N., Wang, M., Yin, G., Shu, G., & Xiao, Q. (2026). Ginkgolide B Inhibits Colorectal Cancer Growth via Regulation of the PI3K/AKT/MAPK Pathways: A Comprehensive Analysis Using Network Pharmacology, Molecular Docking, and Verification in Cellular and Animal Models. Frontiers in Bioscience-Landmark, 31(10). https://doi.org/10.31083/fbl55020

Vancouver

Liu Q, Sun X, Aisikaer A, Altannavch N, Wang M, Yin G, et al. Ginkgolide B Inhibits Colorectal Cancer Growth via Regulation of the PI3K/AKT/MAPK Pathways: A Comprehensive Analysis Using Network Pharmacology, Molecular Docking, and Verification in Cellular and Animal Models. Frontiers in Bioscience-Landmark. 2026;31(10). doi:10.31083/fbl55020

BibTeX
@article{Liu2026,
  author = {Liu, Qi and Sun, Xin and Aisikaer, Aikelimu and Altannavch, Nyamsambuu and Wang, Maonan and Yin, Gang and Shu, Guang and Xiao, Qing},
  title = {Ginkgolide B Inhibits Colorectal Cancer Growth via Regulation of the PI3K/AKT/MAPK Pathways: A Comprehensive Analysis Using Network Pharmacology, Molecular Docking, and Verification in Cellular and Animal Models},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {10},
  doi = {10.31083/fbl55020}
}
Kostenlos starten →